Recursion (NASDAQ: RXRX) and Exscientia PLC (NASDAQ: EXAI) have announced that their shareholders have overwhelmingly approved the proposed combination between the two companies. The transaction is ...

Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...

Recursion is building an industrialized engine for medicine. It operates among biotech stocks, selling access to its proprietary platform and pursuing joint development with major partners like Roche ...

Just when you thought the circular deals couldn’t get any more circular, OpenAI has invested in CEO Sam Altman’s brain computer interface (BCI) startup Merge Labs. Merge Labs, which defines itself as ...

The previous 'Quick Sort' was a 'speed-oriented' method that set a pivot and threw elements to the left or right. In contrast, the 'Merge Sort' introduced this time is an algorithm characterized by 'a ...

OpenAI CEO Sam Altman’s new brain-computer interface startup, Merge Labs, is being spun out of the Los Angeles–based nonprofit Forest Neurotech, according to a source with direct knowledge of the ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...